Galera announces oral presentation at 2022 american society of clinical oncology (asco) annual meeting detailing results from phase 3 roman trial of avasopasem

Avasopasem produced clinically meaningful, statistically significant reduction of severe oral mucositis (som) in patients with locally advanced head and neck cancer receiving radiotherapy

GRTX Ratings Summary

GRTX Quant Ranking